Shots:
- ProQR to receive $20M up front, $30M as an equity investment & is also eligible to receive ~$1.25B as development, regulatory, and commercialization milestones along with royalties on product sales
- The companies collaborated to develop editing oligonucleotides for five targets by using ProQR’s Axiomer RNA editing platform
- ProQR’s Axiomer platform technology enables the editing of single nucleotides in RNA in targeted & specific manner. The technology is designed to recruit endogenous ADAR enzymes to selected target adenosine in a disease-associated RNA
Click here to read full press release/ article | Ref: Globe Newswire | Image: PharmaLive
The post Eli Lilly Signs a License and Research Agreement with ProQR to Develop & Commercialize RNA Therapeutic for the Treatment of Liver and Nervous System Disorders first appeared on PharmaShots.
